Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Inhibrx Biosciences (INBX) EBITDA Margin (2023 - 2025)

Historic EBITDA Margin for Inhibrx Biosciences (INBX) over the last 3 years, with Q2 2025 value amounting to 2106.85%.

  • Inhibrx Biosciences' EBITDA Margin rose 1587911500.0% to 2106.85% in Q2 2025 from the same period last year, while for Sep 2025 it was 11949.57%, marking a year-over-year increase of 61676900.0%. This contributed to the annual value of 165724.0% for FY2024, which is 1535450600.0% down from last year.
  • According to the latest figures from Q2 2025, Inhibrx Biosciences' EBITDA Margin is 2106.85%, which was up 1587911500.0% from 1595.43% recorded in Q1 2025.
  • Inhibrx Biosciences' 5-year EBITDA Margin high stood at 1595.43% for Q1 2025, and its period low was 160898.0% during Q2 2024.
  • Over the past 3 years, Inhibrx Biosciences' median EBITDA Margin value was 21956.66% (recorded in 2023), while the average stood at 49017.42%.
  • As far as peak fluctuations go, Inhibrx Biosciences' EBITDA Margin crashed by -445247600bps in 2024, and later soared by 1587911500bps in 2025.
  • Inhibrx Biosciences' EBITDA Margin (Quarter) stood at 5403.24% in 2023, then crashed by -824bps to 49928.0% in 2024, then soared by 96bps to 2106.85% in 2025.
  • Its last three reported values are 2106.85% in Q2 2025, 1595.43% for Q1 2025, and 49928.0% during Q4 2024.